Calgary, Alberta–(Newsfile Corp. – October 4, 2022) – NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, announced today results from a controlled survey in the Company’s lab showing the effectiveness of the Company’s proprietary small interfering RNA (siRNA) in inhibiting the expression of the phosphatase and tensin homolog (PTEN). Inhibition of PTEN promotes axon regeneration and neural repair[1], key elements for healing after a traumatic spinal cord injury.